Takeda diabetes drug cuts heart attacks

	Tweet

Giving Diabetes patients Takeda Pharmaceutical Co. Ltd.’s drug Actos not only lowers their blood sugar levels but also protects them from heart attacks, researchers said on Monday.

A 5,200-patient clinical study found that Actos, when added to standard therapy, reduced the combined risk of Heart Attacks, Strokes and death by 16 percent in high-risk people with Type 2 diabetes, compared to conventional therapy alone.

Actos, which is co-promoted by Eli Lilly and Co., belongs to a class of medicines called insulin sensitisers that also includes GlaxoSmithKline Plc’s Avandia.

They work by making the body’s cells more sensitive to insulin, thereby helping people with type II, or adult-onset, diabetes to better use their own natural insulin.

The results of the trial on Actos, which is known by the chemical name pioglitazone, were presented at the European Association for the Study of Diabetes congress in Athens. 

RELATED STORIES:
Heart Attack Warning Signs   Statewide Program Helps Improve Quality of Care For Heart Attack   Brief Overview of Heart Failure   Poor memory and slow reactions linked to heart attacks   A tipple a day keeps heart attacks away   Vioxx user was a heart attack waiting to happen   Women Still Get Lower-quality Heart Attack Care than Men   Common Painkillers Associated with Increased Risk of Heart Failure   Optional Programs and Heart Attack Care   Rapid return to work after heart attack OK for some   New drug could reduce heart attack damage   Hormone Therapy May Prevent Heart Attacks for Women in Their 50s

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]